Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation

NCT02892201 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT02892201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02892201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Terminated
Start date
September 8, 2016
Completion date
March 31, 2020
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma